BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

2:24 PM
 | 
Feb 10, 2017
 |  BC Extra  |  Company News

Neurocrine gets rights to Bial-Portela's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (ONO-2370).

Bial-Portela will receive $30 million up front and is...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >